Citi Reiterates Sell Rating on PTC Therapeutics (PTCT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
PTC Therapeutics (PTCT) Announces FDA Target Regulatory Action Date of July 29, 2025 for Sepiapterin and Lancet Publication of Phase 3 Trial Results
October 14, 2024 4:30 PM EDTPTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has set a target regulatory action date of July 29, 2025, for the review of the New Drug Application (NDA) for sepiapterin, consistent with a standard review timeline. The NDA was submitted with an indication for the treatment of pediatric and... More
PTC Therapeutics (PTCT) PT Raised to $45 at Morgan Stanley
October 11, 2024 8:24 AM EDTMorgan Stanley analyst Jeffrey Hung raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $45.00 (from $32.00) while maintaining a Equalweight rating.... More
